Compare EARN & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EARN | SENS |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Industrial Machinery/Components |
| Sector | Real Estate | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 180.3M | 213.2M |
| IPO Year | 2012 | 2014 |
| Metric | EARN | SENS |
|---|---|---|
| Price | $4.81 | $5.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $5.38 | ★ $18.38 |
| AVG Volume (30 Days) | 404.3K | ★ 1.1M |
| Earning Date | 06-16-2026 | 05-08-2026 |
| Dividend Yield | ★ 20.51% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,389,000.00 |
| Revenue This Year | $7.69 | $74.15 |
| Revenue Next Year | $19.57 | $58.60 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 19.85 |
| 52 Week Low | $4.27 | $0.41 |
| 52 Week High | $6.08 | $8.75 |
| Indicator | EARN | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 55.55 | 45.77 |
| Support Level | $4.54 | $5.26 |
| Resistance Level | $4.94 | $8.55 |
| Average True Range (ATR) | 0.08 | 0.48 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 61.78 | 36.46 |
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times. The company primary investment objectives are to generate attractive current yields and risk-adjusted total returns for shareholders. It invest in multiple parts of the CLO capital structure, principally mezzanine debt and equity tranches. Rather than focusing only on short-term current yield, it select investments that it believe will provide a strong total return to drive a sustainable earnings stream over a long-term horizon.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.